Acylcarnitine profile analysis

Disclaimer: These Technical Standards and Guidelines were developed primarily as an educational resource for clinical laboratory geneticists to help them provide quality clinical laboratory genetic services. Adherence to these standards and guidelines is voluntary and does not necessarily assure a successful medical outcome. These Standards and Guidelines should not be considered inclusive of all proper procedures and tests or exclusive of other procedures and tests that are reasonably directed to obtaining the same results. In determining the propriety of any specific procedure or test, the clinical laboratory geneticist should apply his or her own professional judgment to the specific circumstances presented by the individual patient or specimen. Clinical laboratory geneticists are encouraged to document in the patient's record the rationale for the use of a particular procedure or test, whether or not it is in conformance with these Standards and Guidelines. They also are advised to take notice of the date any particular standard or guidelines was adopted, and to consider other relevant medical and scientific information that becomes available after that date.

[1]  Adnya Manjarekar,et al.  Quality Management , 2019, Production and Operations Analysis.

[2]  N. Blau,et al.  Laboratory guide to the methods in biochemical genetics , 2008 .

[3]  D. Driscoll,et al.  First trimester diagnosis and screening for fetal aneuploidy , 2008, Genetics in Medicine.

[4]  J. Charrow,et al.  Development of a newborn screening follow-up algorithm for the diagnosis of isobutyryl-CoA dehydrogenase deficiency , 2007, Genetics in Medicine.

[5]  W Harry Hannon,et al.  Naming and Counting Disorders (Conditions) Included in Newborn Screening Panels , 2006, Pediatrics.

[6]  Michael S. Watson,et al.  Newborn Screening: Toward a Uniform Screening Panel and System—Executive Summary , 2006, Pediatrics.

[7]  B. Casetta,et al.  Falsely elevated C4-carnitine as expression of glutamate formiminotransferase deficiency in tandem mass spectrometry newborn screening. , 2006, Journal of mass spectrometry : JMS.

[8]  Edward R. Ashwood,et al.  Tietz Textbook of Clinical Chemistry and Molecular Diagnostics , 2005 .

[9]  Donald H Chace,et al.  A biochemical perspective on the use of tandem mass spectrometry for newborn screening and clinical testing. , 2005, Clinical biochemistry.

[10]  R. Wanders,et al.  Characterization of carnitine and fatty acid metabolism in the long-chain acyl-CoA dehydrogenase-deficient mouse. , 2005, The Biochemical journal.

[11]  T. Cowan,et al.  The urinary excretion of glutarylcarnitine is an informative tool in the biochemical diagnosis of glutaric acidemia type I. , 2005, Molecular genetics and metabolism.

[12]  S. Henderson,et al.  Preimplantation diagnosis of a lysosomal storage disorder by in situ enzymatic activity: ‘Proof of principle’ in acid sphingomyelinase-deficient mice , 2005, Journal of Inherited Metabolic Disease.

[13]  N. Longo,et al.  Response to therapy in carnitine/acylcarnitine translocase (CACT) deficiency due to a novel missense mutation , 2004, American journal of medical genetics. Part A.

[14]  R. Wanders,et al.  2-Methyl-3-hydroxybutyryl-CoA dehydrogenase deficiency is caused by mutations in the HADH2 gene. , 2003, American journal of human genetics.

[15]  D. Chace,et al.  Electrospray tandem mass spectrometry for analysis of acylcarnitines in dried postmortem blood specimens collected at autopsy from infants with unexplained cause of death. , 2001, Clinical chemistry.

[16]  D. H. Chace.  Mass spectrometry in the clinical laboratory. , 2001, Chemical reviews.

[17]  P. Rinaldo,et al.  Prenatal diagnosis of disorders of fatty acid transport and mitochondrial oxidation , 2001, Prenatal diagnosis.

[18]  D. Millington,et al.  Acylcarnitines in fibroblasts of patients with long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency and other fatty acid oxidation disorders , 2000, Journal of Inherited Metabolic Disease.

[19]  N. Chamoles,et al.  Diagnosis of isovaleric acidaemia by tandem mass spectrometry: False positive result due to pivaloylcarnitine in a newborn screening programme , 1998, Journal of Inherited Metabolic Disease.

[20]  M. Bennett,et al.  Inborn errors of metabolism diagnosed in sudden death cases by acylcarnitine analysis of postmortem bile. , 1995, Clinical chemistry.

[21]  L. Barness,et al.  Diagnosis of inborn errors of metabolism. , 1969, Boletin de la Asociacion Medica de Puerto Rico.

[22]  C. Roe,et al.  Differentiation of long-chain fatty acid oxidation disorders using alternative precursors and acylcarnitine profiling in fibroblasts. , 2006, Molecular genetics and metabolism.

[23]  Newborn screening: toward a uniform screening panel and system. , 2006, Genetics in medicine : official journal of the American College of Medical Genetics.

[24]  S. Olpin.  Fatty acid oxidation defects as a cause of neuromyopathic disease in infants and adults. , 2005, Clinical laboratory.

[25]  W. Gahl,et al.  Revised Sections F7.5 (Quantitative Amino Acid Analysis) and F7.6 (Qualitative Amino Acid Analysis): American College of Medical Genetics Standards and Guidelines for Clinical Genetics Laboratories, 2003 , 2004, Genetics in Medicine.

[26]  D. Millington,et al.  Tandem Mass Spectrometry in Clinical Diagnosis , 2003 .

[27]  Hilde van der Togt,et al.  Publisher's Note , 2003, J. Netw. Comput. Appl..

[28]  M. Durán,et al.  Physician’s Guide to the Laboratory Diagnosis of Metabolic Diseases , 2003, Springer Berlin Heidelberg.

[29]  Piero Rinaldo,et al.  Fatty acid oxidation disorders. , 2002, Annual review of physiology.